These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 15013589

  • 1. A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies.
    Forouzannia A, Schiller J, Berlin J, Hutson P, Boothman D, Storer B, Wilding G, Mehta M.
    Lung Cancer; 2004 Apr; 44(1):111-9. PubMed ID: 15013589
    [Abstract] [Full Text] [Related]

  • 2. Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain.
    Varveris H, Petinelli E, Stratakis J, Mazonakis M.
    Oncol Rep; 2008 Feb; 19(2):447-55. PubMed ID: 18202794
    [Abstract] [Full Text] [Related]

  • 3. Prolonged infusional topotecan and accelerated hyperfractionated 3d-conformal radiation in patients with newly diagnosed glioblastoma--a phase I study.
    Grabenbauer GG, Anders K, Fietkau RJ, Klautke G, Feldmann HJ, Weiser S, Staab HJ, Krauseneck P, Sauer R.
    J Neurooncol; 2002 Dec; 60(3):269-75. PubMed ID: 12510778
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Lu C, Komaki R, Lee JS, Shin DM, Palmer JL, Coldman BJ, Pisters KM, Kurie JM, Fossella FV, Glisson BS.
    Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
    [Abstract] [Full Text] [Related]

  • 5. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
    Vokes EE, Haraf DJ, Drinkard LC, Hoffman PC, Ferguson MK, Vogelzang NJ, Watson S, Lane NJ, Golomb HM.
    Cancer Chemother Pharmacol; 1995 Jun; 35(4):304-12. PubMed ID: 7530173
    [Abstract] [Full Text] [Related]

  • 6. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S, Kouroussis C, Souglakos J, Mavroudis D, Agelaki S, Kalbakis K, Androulakis N, Vardakis N, Vamvakas L, Georgoulias V.
    Oncology; 2001 Jun; 61(4):265-70. PubMed ID: 11721172
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II study of IV topotecan in combination with whole brain radiation for the treatment of brain metastases.
    Mirmiran A, McClay E, Spear MA.
    Med Oncol; 2007 Jun; 24(2):147-53. PubMed ID: 17848737
    [Abstract] [Full Text] [Related]

  • 8. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.
    Ghesquières H, Faivre S, Djafari L, Pautier P, Lhommé C, Lozahic S, Djazouli K, Armand JP, Raymond E.
    Invest New Drugs; 2006 Sep; 24(5):413-21. PubMed ID: 16763786
    [Abstract] [Full Text] [Related]

  • 9. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulias V.
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [Abstract] [Full Text] [Related]

  • 10. Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study.
    Stathopoulos GP, Ardavanis A, Papakotoulas P, Pectasides D, Papadopoulos G, Antoniou D, Athanasiadis A, Trafalis D, Anagnostopoulos A, Koutantos J, Vaslamatzis M.
    Anticancer Drugs; 2010 Feb; 21(2):202-5. PubMed ID: 20010424
    [Abstract] [Full Text] [Related]

  • 11. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children's Cancer Group-0952.
    Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP.
    Neuro Oncol; 2003 Jan; 5(1):8-13. PubMed ID: 12626128
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.
    Fisher BJ, Scott C, Macdonald DR, Coughlin C, Curran WJ.
    J Clin Oncol; 2001 Feb 15; 19(4):1111-7. PubMed ID: 11181676
    [Abstract] [Full Text] [Related]

  • 13. Phase I study of topotecan and radiation therapy in advanced cervical cancer.
    Dunton CJ, King SA, Neufeld J, Tolosa J, Perez G, Avila A, Underhill K.
    Gynecol Oncol; 2002 Apr 15; 85(1):185-7. PubMed ID: 11925142
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.
    Masters GA, Haraf DJ, Hoffman PC, Drinkard LC, Krauss SA, Ferguson MK, Olak J, Samuels BL, Golomb HM, Vokes EE.
    J Clin Oncol; 1998 Jun 15; 16(6):2157-63. PubMed ID: 9626216
    [Abstract] [Full Text] [Related]

  • 15. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Choi NC, Herndon JE, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M.
    J Clin Oncol; 1998 Nov 15; 16(11):3528-36. PubMed ID: 9817271
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer.
    Choi B, Robins HI, Schiller J, Mehta M.
    Cancer Chemother Pharmacol; 2008 Dec 15; 63(1):175-9. PubMed ID: 18305938
    [Abstract] [Full Text] [Related]

  • 17. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
    Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF, Kozelsky TF, Jett JR.
    Int J Radiat Oncol Biol Phys; 2007 Mar 15; 67(4):995-1001. PubMed ID: 17336213
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases.
    Kocher M, Eich HT, Semrau R, Güner SA, Müller RP.
    Strahlenther Onkol; 2005 Jan 15; 181(1):20-5. PubMed ID: 15660189
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of oral topotecan in hematological malignancies.
    Beran M, O'Brien S, Thomas DA, Tran HT, Cortes-Franco JE, Giles F, Estey E, Kantarjian HM.
    Clin Cancer Res; 2003 Sep 15; 9(11):4084-91. PubMed ID: 14519630
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
    Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ.
    J Clin Oncol; 1998 Oct 15; 16(10):3302-9. PubMed ID: 9779705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.